Although the cancer-related PPARγ mutants—which are mainly scattered throughout the LBD (Figure 2)—may display variable and more subtle, i.e., context-dependent, intra- and/or intermolecular defects than the FPLD3-associated PPARγ, the cancer-related PPARγ mutants (Figure 2) are impaired in their ability to exert “classical” transactivation. The gene discussed is PPARG; the disease is cancer.